AstraZeneca PLC (NASDAQ:AZN) is among the best-performing European stocks to invest in, as confirmed by Goldman Sachs after Phase 3 trial data for baxdrostat was released at ESC 2025. The trial found baxdrostat reduced seated systolic blood pressure in a dose-dependent manner at week 12.

Safety data revealed confirmed rates of moderate to severe hyperkalemia were 1.1% for both the 2 mg and 1 mg doses, compared to 0% for the placebo. Discontinuation rates due to adverse reactions were 4.5% for the 2 mg dose and 2.7% for the 1 mg dose, compared to 1.9% for the placebo.

During a conference call, management stated that baxdrostat did not have any clinically significant drug-drug interactions, which is promising for potential use in clinical trials. AstraZeneca PLC (NASDAQ:AZN) is a key player in the pharmaceutical sector, particularly for rare disease and cancer treatments, with a strong reputation in healthcare.

While AstraZeneca (AZN) shows promise as an investment, some AI stocks may offer greater upside potential with less downside risk. For an undervalued AI stock that could benefit from Trump-era tariffs and the onshoring trend, check out the best short-term AI stock.

Read more at Yahoo Finance: AstraZeneca (AZN) Price Target Backed by Goldman After Baxdrostat Phase 3 Data